Heres what the clinical data shows: Most Common: Nausea (affecting 15-44% of users), diarrhea (10-30%), vomiting (7-25%), and constipation (6-24%) Severity: 98.1% of gastrointestinal side effects are mild or moderate, with 99.5% being non-serious Duration: Median duration is 8 days for nausea, 3 days for diarrhea, and 2 days for vomiting Timing: Most side effects occur during initial weeks and dose escalation, declining over time Discontinuation: Only 4.3-10% of users discontinue therapy due to side effects Serious Events: Rare, with no increased risk of pancreatitis or malignancy in clinical trials Management: Slow dose titration, dietary modifications, and hydration significantly reduce symptoms Important Note: Weight loss is NOT caused by side effects
Goal: Support reduction of fat mass and enhance fat oxidation over time
Cavernous artery flow and end-diastolic velocity were normal: peak systolic velocity = 98 cm/seconds on the right and 96 cm/seconds on the left
10.26402/jpp.2018.3.11
Vomiting occurred in 11% of participants and was similar between the drug and placebo groups
Chronic inflammation degrades the extracellular matrix, disrupts collagen architecture, and impairs the skin barrier function